Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of CC-90006 in Subjects With Mild to Moderate Plaque-type Psoriasis
NCT03337022
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
34
Enrollment
INDUSTRY
Sponsor class
Conditions
Psoriasis
Interventions
DRUG:
CC-90006
OTHER:
Placebo
Sponsor
Celgene